Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.

Arsenic trioxide (As(2)O(3)) is a highly effective treatment for patients with relapsed acute promyelocytic leukemia (APL); its role as consolidation treatment for patients in first remission has not been defined. We randomized 481 patients (age ≥ 15 years) with untreated APL to either a standard induction regimen of tretinoin, cytarabine, and daunorubicin, followed by 2 courses of consolidation therapy with tretinoin plus daunorubicin, or to the same induction and consolidation regimen plus two 25-day courses of As(2)O(3) consolidation immediately after induction. After consolidation, patients were randomly assigned to one year of maintenance therapy with either tretinoin alone or in combination with methotrexate and mercaptopurine. Ninety percent of patients on each arm achieved remission and were eligible to receive their assigned consolidation therapy. Event-free survival, the primary end point, was significantly better for patients assigned to receive As(2)O(3) consolidation, 80% compared with 63% at 3 years (stratified log-rank test, P < .0001). Survival, a secondary end point, was better in the As(2)O(3) arm, 86% compared with 81% at 3 years (P = .059). Disease-free survival, a secondary end point, was significantly better in the As(2)O(3) arm, 90% compared with 70% at 3 years (P < .0001). The addition of As(2)O(3) consolidation to standard induction and consolidation therapy significantly improves event-free and disease-free survival in adults with newly diagnosed APL. This trial was registered at clinicaltrials.gov (NCT00003934).
AuthorsBayard L Powell, Barry Moser, Wendy Stock, Robert E Gallagher, Cheryl L Willman, Richard M Stone, Jacob M Rowe, Steven Coutre, James H Feusner, John Gregory, Stephen Couban, Frederick R Appelbaum, Martin S Tallman, Richard A Larson
JournalBlood (Blood) Vol. 116 Issue 19 Pg. 3751-7 (Nov 11 2010) ISSN: 1528-0020 [Electronic] United States
PMID20705755 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural)
Chemical References
  • Arsenicals
  • Oxides
  • Cytarabine
  • Tretinoin
  • 6-Mercaptopurine
  • arsenic trioxide
  • Methotrexate
  • Daunorubicin
  • 6-Mercaptopurine (administration & dosage)
  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
  • Arsenicals (administration & dosage)
  • Cytarabine (administration & dosage)
  • Daunorubicin (administration & dosage)
  • Disease-Free Survival
  • Female
  • Humans
  • Leukemia, Promyelocytic, Acute (drug therapy, mortality)
  • Male
  • Methotrexate (administration & dosage)
  • Middle Aged
  • North America
  • Oxides (administration & dosage)
  • Survival Analysis
  • Treatment Outcome
  • Tretinoin (administration & dosage)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: